Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2018, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 1, 37, 33, 29, 78, 17 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 25 and 6 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
A1M Pharma AB
Acceleron Pharma Inc
Ache Laboratorios Farmaceuticos SA
Actelion Pharmaceuticals Ltd
Aerogen Ltd
Anavex Life Sciences Corp
AnGes Inc
Arena Pharmaceuticals Inc
Ascendia Pharmaceuticals LLC
Ascendis Pharma A/S
AVEO Pharmaceuticals Inc
Bayer AG
Bial - Portela & Ca SA
Bioblue Technologies Inc
Biogen Inc
Biolab Farmaceutica Ltda
BioRestorative Therapies Inc
Boryung Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
CJ HealthCare Corp
Complexa Inc
Corion Biotech Srl
Cumberland Pharmaceuticals Inc
D. Western Therapeutics Institute Inc
Daewon Pharm Co Ltd
Daewoong Co Ltd
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Eli Lilly and Co
Esperion Therapeutics Inc
FunPep Co Ltd
Galectin Therapeutics Inc
Gemphire Therapeutics Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
H. Lundbeck AS
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Idorsia Pharmaceutical Ltd
Ildong Pharmaceutical Co Ltd
Innopharmax Inc
Insmed Inc
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
Japan Tobacco Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
KBP BioSciences Co Ltd
Leading BioSciences Inc
Lee's Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
LG Chem Ltd
LinXis BV
Liquidia Technologies Inc
MannKind Corp
Marina Biotech Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
N4 Pharma Plc
Nippon Shinyaku Co Ltd
Nissan Chemical Industries Ltd
Northern Therapeutics Inc
Novartis AG
Omeros Corp
Orion Corporation
Peloton Therapeutics Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Pulmokine Inc
Quantum Genomics SA
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
Relypsa Inc
Renova Therapeutics Inc
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
rEVO Biologics Inc
Roivant Sciences Ltd
Rottapharm Biotech Srl
Sanofi
Sarfez Pharmaceuticals Inc
Serodus ASA
Shanghai Pharmaceutical Co Ltd
SJT Molecular Research SL
SteadyMed Therapeutics Inc
Suda Pharmaceuticals Ltd
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Target Medicals LLC
The Medicines Company
Theracos Inc
Theravance Biopharma Inc
Toray Industries Inc
United Therapeutics Corp
Vascular BioSciences
VG Life Sciences Inc
Vicore Pharma AB
Vivus Inc
XuanZhu Pharma Co Ltd
Yuhan Corp
'
Table of Contents
Table of Contents 2
Introduction 7
Hypertension - Overview 8
Hypertension - Therapeutics Development 9
Hypertension - Therapeutics Assessment 34
Hypertension - Companies Involved in Therapeutics Development 52
Hypertension - Drug Profiles 103
Hypertension - Dormant Projects 539
Hypertension - Discontinued Products 556
Hypertension - Product Development Milestones 558
Appendix 567
List of Tables
Number of Products under Development for Hypertension, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Products under Development by Companies, H1 2018 (Contd..11), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hypertension - Pipeline by A1M Pharma AB, H1 2018
Hypertension - Pipeline by Acceleron Pharma Inc, H1 2018
Hypertension - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018
Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018
Hypertension - Pipeline by Aerogen Ltd, H1 2018
Hypertension - Pipeline by Anavex Life Sciences Corp, H1 2018
Hypertension - Pipeline by AnGes Inc, H1 2018
Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by Ascendia Pharmaceuticals LLC, H1 2018
Hypertension - Pipeline by Ascendis Pharma A/S, H1 2018
Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by Bayer AG, H1 2018
Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2018
Hypertension - Pipeline by Bioblue Technologies Inc, H1 2018
Hypertension - Pipeline by Biogen Inc, H1 2018
Hypertension - Pipeline by Biolab Farmaceutica Ltda, H1 2018
Hypertension - Pipeline by BioRestorative Therapies Inc, H1 2018
Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by Bristol-Myers Squibb Co, H1 2018
Hypertension - Pipeline by Camurus AB, H1 2018
Hypertension - Pipeline by Capricor Therapeutics Inc, H1 2018
Hypertension - Pipeline by Celsion Corp, H1 2018
Hypertension - Pipeline by Celtaxsys Inc, H1 2018
Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2018
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by CJ HealthCare Corp, H1 2018
Hypertension - Pipeline by Complexa Inc, H1 2018
Hypertension - Pipeline by Corion Biotech Srl, H1 2018
Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H1 2018
Hypertension - Pipeline by Daewon Pharm Co Ltd, H1 2018
Hypertension - Pipeline by Daewoong Co Ltd, H1 2018
Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Hypertension - Pipeline by Denovo Biopharma LLC, H1 2018
Hypertension - Pipeline by Eli Lilly and Co, H1 2018
Hypertension - Pipeline by Esperion Therapeutics Inc, H1 2018
Hypertension - Pipeline by FunPep Co Ltd, H1 2018
Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2018
Hypertension - Pipeline by Gemphire Therapeutics Inc, H1 2018
Hypertension - Pipeline by Gilead Sciences Inc, H1 2018
Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2018
Hypertension - Pipeline by H. Lundbeck AS, H1 2018
Hypertension - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Hypertension - Pipeline by Idorsia Pharmaceutical Ltd, H1 2018
Hypertension - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by Innopharmax Inc, H1 2018
Hypertension - Pipeline by Insmed Inc, H1 2018
Hypertension - Pipeline by Insys Therapeutics Inc, H1 2018
Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by Japan Tobacco Inc, H1 2018
Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by Johnson & Johnson, H1 2018
Hypertension - Pipeline by KBP BioSciences Co Ltd, H1 2018
Hypertension - Pipeline by Leading BioSciences Inc, H1 2018
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2018
Hypertension - Pipeline by LG Chem Ltd, H1 2018
Hypertension - Pipeline by LinXis BV, H1 2018
Hypertension - Pipeline by Liquidia Technologies Inc, H1 2018
Hypertension - Pipeline by MannKind Corp, H1 2018
Hypertension - Pipeline by Marina Biotech Inc, H1 2018
Hypertension - Pipeline by Merck & Co Inc, H1 2018
Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2018
Hypertension - Pipeline by N4 Pharma Plc, H1 2018
Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2018
Hypertension - Pipeline by Nissan Chemical Industries Ltd, H1 2018
Hypertension - Pipeline by Northern Therapeutics Inc, H1 2018
Hypertension - Pipeline by Novartis AG, H1 2018
Hypertension - Pipeline by Omeros Corp, H1 2018
Hypertension - Pipeline by Orion Corporation, H1 2018
Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2018
Hypertension - Pipeline by Pfizer Inc, H1 2018
Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by Pulmokine Inc, H1 2018
Hypertension - Pipeline by Quantum Genomics SA, H1 2018
Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by Relief Therapeutics Holding AG, H1 2018
Hypertension - Pipeline by Relypsa Inc, H1 2018
Hypertension - Pipeline by Renova Therapeutics Inc, H1 2018
Hypertension - Pipeline by Respira Therapeutics Inc, H1 2018
Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by rEVO Biologics Inc, H1 2018
Hypertension - Pipeline by Roivant Sciences Ltd, H1 2018
Hypertension - Pipeline by Rottapharm Biotech Srl, H1 2018
Hypertension - Pipeline by Sanofi, H1 2018
Hypertension - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018
Hypertension - Pipeline by Serodus ASA, H1 2018
Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by SJT Molecular Research SL, H1 2018
Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2018
Hypertension - Pipeline by Suda Pharmaceuticals Ltd, H1 2018
Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018
Hypertension - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Hypertension - Pipeline by Target Medicals LLC, H1 2018
Hypertension - Pipeline by The Medicines Company, H1 2018
Hypertension - Pipeline by Theracos Inc, H1 2018
Hypertension - Pipeline by Theravance Biopharma Inc, H1 2018
Hypertension - Pipeline by Toray Industries Inc, H1 2018
Hypertension - Pipeline by United Therapeutics Corp, H1 2018
Hypertension - Pipeline by Vascular BioSciences, H1 2018
Hypertension - Pipeline by VG Life Sciences Inc, H1 2018
Hypertension - Pipeline by Vicore Pharma AB, H1 2018
Hypertension - Pipeline by Vivus Inc, H1 2018
Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H1 2018
Hypertension - Pipeline by Yuhan Corp, H1 2018
Hypertension - Dormant Projects, H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..1), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..2), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..3), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..4), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..5), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..6), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..7), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..8), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..9), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..10), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..11), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..12), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..13), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..14), H1 2018
Hypertension - Dormant Projects, H1 2018 (Contd..15), H1 2018
Hypertension - Discontinued Products, H1 2018
Hypertension - Discontinued Products, H1 2018 (Contd..1), H1 2018
List of Figures
Number of Products under Development for Hypertension, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
